CN102821759A - 用于治疗具有慢性活性b细胞受体信号传导的b细胞淋巴瘤的pkc抑制剂 - Google Patents

用于治疗具有慢性活性b细胞受体信号传导的b细胞淋巴瘤的pkc抑制剂 Download PDF

Info

Publication number
CN102821759A
CN102821759A CN2011800155365A CN201180015536A CN102821759A CN 102821759 A CN102821759 A CN 102821759A CN 2011800155365 A CN2011800155365 A CN 2011800155365A CN 201180015536 A CN201180015536 A CN 201180015536A CN 102821759 A CN102821759 A CN 102821759A
Authority
CN
China
Prior art keywords
inhibitor
pkc
additional agent
diketone
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800155365A
Other languages
English (en)
Chinese (zh)
Inventor
W·舒勒
F·P·施特格梅尔
M·瓦姆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of CN102821759A publication Critical patent/CN102821759A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2011800155365A 2010-03-30 2011-03-28 用于治疗具有慢性活性b细胞受体信号传导的b细胞淋巴瘤的pkc抑制剂 Pending CN102821759A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31901310P 2010-03-30 2010-03-30
US61/319,013 2010-03-30
US201061425525P 2010-12-21 2010-12-21
US61/425,525 2010-12-21
PCT/EP2011/054709 WO2011120911A1 (en) 2010-03-30 2011-03-28 Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling

Publications (1)

Publication Number Publication Date
CN102821759A true CN102821759A (zh) 2012-12-12

Family

ID=44710357

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800155365A Pending CN102821759A (zh) 2010-03-30 2011-03-28 用于治疗具有慢性活性b细胞受体信号传导的b细胞淋巴瘤的pkc抑制剂

Country Status (12)

Country Link
US (1) US8748428B2 (https=)
EP (1) EP2552428A1 (https=)
JP (1) JP2013523678A (https=)
KR (2) KR101461767B1 (https=)
CN (1) CN102821759A (https=)
AR (1) AR080737A1 (https=)
AU (1) AU2011234644B2 (https=)
BR (1) BR112012024585A2 (https=)
CA (1) CA2795456A1 (https=)
MX (1) MX2012011341A (https=)
RU (1) RU2012146083A (https=)
WO (1) WO2011120911A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106795151A (zh) * 2014-08-06 2017-05-31 诺华股份有限公司 蛋白激酶c抑制剂和它们的使用方法
WO2019218810A1 (zh) * 2018-05-17 2019-11-21 复旦大学附属肿瘤医院 治疗非霍奇金氏淋巴瘤的药物组合物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3018133T3 (en) 2011-11-30 2025-05-14 Univ Emory Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
KR101723786B1 (ko) 2014-03-28 2017-04-06 가톨릭대학교 산학협력단 Ｉｌ―２１을 발현하는 중간엽 줄기세포를 포함하는 ｂ 세포 림프종 예방 또는 치료용 조성물
AU2017295858A1 (en) 2016-07-14 2019-01-24 Mingsight Pharmaceuticals, Inc. Treatment of cancer
WO2020092924A1 (en) * 2018-11-02 2020-05-07 Board Of Regents, The University Of Texas System Combination therapy for the treatment of egfr tyrosine kinase inhibitor resistant cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038561A1 (en) * 2000-11-07 2002-05-16 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
WO2007006533A2 (en) * 2005-07-11 2007-01-18 Novartis Ag Indolylmaleimide derivatives
US7235555B2 (en) * 2002-04-03 2007-06-26 Novartis Ag Indolylmaleimide derivatives

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489608A (en) 1989-12-21 1996-02-06 Goedecke Aktiengesellschaft Indolocarbazole derivatives and the use thereof
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
PT657458E (pt) 1993-12-07 2002-02-28 Lilly Co Eli Inibidores de proteina cinase c
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
CA2179650C (en) 1993-12-23 2007-10-30 William Francis Heath, Jr. Bisindolemaleimides and their use as protein kinase c inhibitors
SI0776895T1 (en) 1995-11-20 1999-04-30 Eli Lilly And Company Protein kinase C inhibitor
US6645970B2 (en) * 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
PT1478648E (pt) 2002-02-01 2014-07-15 Ariad Pharma Inc Compostos contendo fósforo e suas utilizações
BRPI0409263A (pt) 2003-04-09 2006-03-28 Millennium Pharm Inc composto; composição farmacêutica; método para tratar uma doença mediada por ikk e método para inibir ikk em um paciente que dele necessita
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
WO2005041953A1 (en) 2003-10-24 2005-05-12 Eli Lilly And Company Bisindolyl maleimides useful for treating prostate cancer and akt-mediated diseases
EP1799699A1 (en) 2004-10-13 2007-06-27 Wyeth Analogs of 17-hydroxywortmannin as pi3k inhibitors
CA2599320A1 (en) 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
JP2008531538A (ja) 2005-02-25 2008-08-14 クドス ファーマシューティカルズ リミテッド ２，４−ジアミノ−ピリドピリミジン誘導体とｍＴＯＲ阻害剤としてのその使用
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
JP5161102B2 (ja) 2005-11-22 2013-03-13 クドス ファーマシューティカルズ リミテッド ｍＴＯＲ阻害剤としてのピリドピリミジン、ピラゾピリミジンおよびピリミドピリミジン誘導体
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP1979325A1 (en) 2006-01-11 2008-10-15 AstraZeneca AB Morpholino pyrimidine derivatives and their use in therapy
CA2659851C (en) 2006-08-23 2014-02-25 Kudos Pharmaceuticals Limited 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
MX2009005950A (es) 2006-12-07 2009-10-12 Genentech Inc Compuestos inhibidores de fosfoinositido 3-quinasas y metodos de uso.
AR066879A1 (es) 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
EP2205242B1 (en) 2007-09-12 2015-04-15 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
JP5348725B2 (ja) 2007-10-25 2013-11-20 ジェネンテック， インコーポレイテッド チエノピリミジン化合物の製造方法
CA2730930C (en) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038561A1 (en) * 2000-11-07 2002-05-16 Novartis Ag Indolylmaleimide derivatives as protein kinase c inhibitors
US7235555B2 (en) * 2002-04-03 2007-06-26 Novartis Ag Indolylmaleimide derivatives
WO2007006533A2 (en) * 2005-07-11 2007-01-18 Novartis Ag Indolylmaleimide derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAVIS R E ET AL: "Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma", 《NATURE》, vol. 463, no. 7277, 7 January 2010 (2010-01-07), pages 88 - 92, XP002646596, DOI: doi:10.1038/NATURE08638 *
LISA PLEYER ET AL: "Molecular and cellular mechanisms of cll: novel therapeutic approaches", 《NATURE REVIEW CLINICAL ONCOLOGY》, vol. 6, no. 7, 31 December 2009 (2009-12-31), pages 405 - 418, XP002646598, DOI: doi:10.1038/nrclinonc.2009.72 *
MCCALL M ET AL: "Sotrastaurin. Protein kinase C inhibitor treatment of transplant rejection treatment of psoriasis treatment of uveitis", 《DRUGS OF THE FUTURE》, vol. 34, no. 8, 31 December 2009 (2009-12-31), pages 618 - 623, XP002646597, DOI: doi:10.1358/dof.2009.34.8.1401067 *
ROSSI RANDALL M ET AL: "Inhibition of Human Lymphoma Cell Growth by the PKC-Beta Selective Inhibitor Enzastaurin（LY317615）in Combination with Multiple Therapeutic Agents", 《BLOOD》, vol. 112, no. 11, 31 December 2008 (2008-12-31), pages 565 - 566, XP008137914 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106795151A (zh) * 2014-08-06 2017-05-31 诺华股份有限公司 蛋白激酶c抑制剂和它们的使用方法
US10508101B2 (en) 2014-08-06 2019-12-17 Novartis Ag Protein kinase C inhibitors and methods of their use
CN106795151B (zh) * 2014-08-06 2021-05-07 诺华股份有限公司 蛋白激酶c抑制剂和它们的使用方法
US11059804B2 (en) 2014-08-06 2021-07-13 Novartis Ag Protein kinase C inhibitors and methods of their use
US11505541B2 (en) 2014-08-06 2022-11-22 Novartis Ag Protein kinase C inhibitors and methods of their use
WO2019218810A1 (zh) * 2018-05-17 2019-11-21 复旦大学附属肿瘤医院 治疗非霍奇金氏淋巴瘤的药物组合物
CN110496223A (zh) * 2018-05-17 2019-11-26 复旦大学附属肿瘤医院 一种治疗非霍奇金氏淋巴瘤的药物组合物

Also Published As

Publication number Publication date
MX2012011341A (es) 2012-11-12
EP2552428A1 (en) 2013-02-06
WO2011120911A1 (en) 2011-10-06
JP2013523678A (ja) 2013-06-17
AU2011234644B2 (en) 2014-07-17
AU2011234644A1 (en) 2012-10-11
US20110245256A1 (en) 2011-10-06
KR101461767B1 (ko) 2014-11-13
KR20140107685A (ko) 2014-09-04
KR20120133389A (ko) 2012-12-10
AR080737A1 (es) 2012-05-02
BR112012024585A2 (pt) 2016-05-31
RU2012146083A (ru) 2014-05-10
US8748428B2 (en) 2014-06-10
CA2795456A1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
US9993480B2 (en) mTOR/JAK inhibitor combination therapy
CN105849110B (zh) 使用溴结构域和额外终端(bet)蛋白抑制剂的用于癌症的组合疗法
KR102320190B1 (ko) 아필리모드 조성물 및 이를 사용하기 위한 방법
WO2016123054A2 (en) Kinase drug combinations and methods of use thereof
US8748428B2 (en) Use of a PKC inhibitor
JP2021506765A (ja) Ｄｕｘ４の発現に関連する疾患の治療のための化合物
WO2017156350A1 (en) Methods of cancer treatment
CN117794540A (zh) 用于治疗b细胞恶性肿瘤的组合物
WO2007143629A1 (en) Treatment of neurofibromatosis with inhibitors of a signal transduction pathway
Criado et al. New small molecules in dermatology: for the autoimmunity, inflammation and beyond
KR20160090814A (ko) Jak, cdk 및 pim의 억제제를 포함하는 조합 요법
EA021951B1 (ru) Противораковая комбинация
JP2020528052A (ja) がん治療におけるエリブリン及びサイクリン依存的キナーゼ阻害剤の使用
WO2006071966A2 (en) Rapamycin compounds in the treatment of neurofibromatosis type 1
KR20250151363A (ko) 골수증식성 신생물의 치료 방법
Gridelli et al. A Randomized Phase II Study of Pemetrexed or RAD001 as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer in Elderly Patients: Treatment Rationale and Protocol Dynamics
WO2013059548A1 (en) Compositions and methods for treating cancer using jak2 inhibitor
TW201139417A (en) Use of a PKC inhibitor
WO2025181153A1 (en) Use of atr inhibitors in combination with pi3k alpha inhibitors
KR20170015218A (ko) 3-[(3-｛[4-(4-모르폴리닐메틸)-1h-피롤-2-일]메틸렌｝-2-옥소-2,3-디하이드로-1h-인돌-5-일)메틸]-1,3-티아졸리딘-2,4-디온과 egfr tyr 키나제 억제제 사이의 신규한 회합물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Basel

Applicant after: Novartis Ag

Address before: Basel

Applicant before: Novartis Vaccines & Diagnostic

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: NOVARTIS VACCINES + DIAGNOSTIC TO: NOVARTIS CO., LTD.

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121212